[
  {
    "ts": null,
    "headline": "3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats",
    "summary": "Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.",
    "url": "https://finnhub.io/api/news?id=9b78f82e7ef2e96c411b30182301cb1fd0565dda1b091c3f65237d7e8de63b0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749475740,
      "headline": "3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats",
      "id": 135137372,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.",
      "url": "https://finnhub.io/api/news?id=9b78f82e7ef2e96c411b30182301cb1fd0565dda1b091c3f65237d7e8de63b0c"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript",
    "summary": "Viatris Inc. (NASDAQ:VTRS) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ParticipantsCorinne M.",
    "url": "https://finnhub.io/api/news?id=b94bc851e054d2ea3dce309b5812bc55aea78e0bbd6238a62aff55eac3b2c503",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749474390,
      "headline": "Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript",
      "id": 135136896,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VTRS",
      "source": "SeekingAlpha",
      "summary": "Viatris Inc. (NASDAQ:VTRS) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ParticipantsCorinne M.",
      "url": "https://finnhub.io/api/news?id=b94bc851e054d2ea3dce309b5812bc55aea78e0bbd6238a62aff55eac3b2c503"
    }
  },
  {
    "ts": null,
    "headline": "Transcript : Viatris Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10",
    "summary": "Presenter SpeechUnknown Analyst Great. Well, thank you, everyone, for joining us. We're very pleased to have Viatris today. And with us, we have Scott Smith, CEO; Theodora Mistras, Chief Financial...",
    "url": "https://finnhub.io/api/news?id=52f1deca253181e257c02a5d665dfd7435fd3ebe4d44e4a6fc1f92dce0122b66",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749472525,
      "headline": "Transcript : Viatris Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10",
      "id": 135136552,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "Presenter SpeechUnknown Analyst Great. Well, thank you, everyone, for joining us. We're very pleased to have Viatris today. And with us, we have Scott Smith, CEO; Theodora Mistras, Chief Financial...",
      "url": "https://finnhub.io/api/news?id=52f1deca253181e257c02a5d665dfd7435fd3ebe4d44e4a6fc1f92dce0122b66"
    }
  },
  {
    "ts": null,
    "headline": "VTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost Review",
    "summary": "Medication company Viatris (NASDAQ:VTRS) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. Its non-GAAP EPS of $0.50 per share was 2.3% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=ef8cced8f3bde6d94557f8ffb33727c9f06ad43c028c0870971b2a5680d9a177",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749468175,
      "headline": "VTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost Review",
      "id": 135149482,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Medication company Viatris (NASDAQ:VTRS) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. Its non-GAAP EPS of $0.50 per share was 2.3% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=ef8cced8f3bde6d94557f8ffb33727c9f06ad43c028c0870971b2a5680d9a177"
    }
  }
]